NATCO Pharma clears $140M rights issue to fund overseas deals
What's the deal? NATCO PharmaDealroom has a profile for this one. Try Dealroom →'s board has approved raising up to ₹1,300 crore — about $140 million — through a rights issue of fully paid-up equity shares with a ₹2 face value, offered to existing shareholders. The Indian drugmaker announced the approval on September 9, 2026.
Why now? The move follows a separate ₹2,000 crore Qualified Institutional Placement limit approved on August 14, 2026, giving NATCO a dual-track fundraising plan. Together, the channels build a cash reserve for global acquisitions.
What's the endgame? The capital is earmarked for inorganic expansion into diversified, branded emerging markets. That follows NATCO's recent purchase of an additional 13.25% stake in South Africa's Adcock Ingram HoldingsDealroom has a profile for this one. Try Dealroom → for ₹1,060 crore.
By the numbers: Consolidated first-quarter revenue for the period ended June 30, 2026, fell 44.7% year-on-year to ₹735.2 crore, from ₹1,328.9 crore. Net profit dropped 57% to ₹206.5 crore, from ₹480.3 crore, hit by weaker sales of the generic oncology drug lenalomide.
What could go wrong? The combined rights issue and QIP create an equity dilution overhang that could weigh on the stock near term. NATCO already holds internal cash reserves of roughly ₹3,500 crore.
The signal: The back-to-back approvals mark an aggressive capital-gathering phase as NATCO pivots away from its volatile US generic oncology pipeline toward branded emerging markets. A war chest of this size points to larger acquisition announcements ahead.
Read more: sahi.com
Image credit: Monash Public Library Service
